Purple Biotech Ltd ADR (PPBT)

$0.59 +0.02 (4.05%)
Market Cap 7.63M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 142,800
Avg Vol 1,234,188
Day's Range N/A - N/A
Shares Out 12.85M
Stochastic %K 63%
Beta 0.61
Analysts Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Stocksavior14
Stocksavior14 Oct. 3 at 10:28 PM
$PPBT the permabulls seem to be using alt accounts now but when they are here just to pump. It’s hard for them to change the way they talk to even hide it. Just like the one guy that talks shit to me and calls me cumsavior very similar to the other permabull that would call me cocksavior LOL
1 · Reply
Purplepayday
Purplepayday Oct. 3 at 9:45 PM
$PPBT weird… But, this @Novafudster sound just like Smitty… Any chance that you are related 🤔
1 · Reply
NovaFoster
NovaFoster Oct. 3 at 9:03 PM
$PPBT yes
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:42 PM
$PPBT are you seriously posting explosions and pumping that an institution holds a whopping $7,000 worth of this stock LOL Most permabulls in here have way more than that invested in here at a loss. LOL🤦🏼‍♂️🤦🏼‍♂️🤣🤣
1 · Reply
NovaFoster
NovaFoster Oct. 3 at 8:38 PM
💥 $PPBT 💥 GAMMA Investing just filed a 13F showing 185% increase in their position — now holding 12,654 shares vs 4,430 last quarter. 📊 That’s institutional accumulation, not selling. Float remains tiny, valuation under $10M, and pipeline news could be a game-changer. Funds are quietly loading — the writing is on the wall. 🚀 #PPBT #Biotech
1 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:06 PM
$PPBT we should be getting our non compliance notice soon. Then a 3rd reverse split is on deck LOL
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:06 PM
$PPBT that’s how hedges make money. It’s harder to rob each other since they all have access to more data…. So they have to manipulate and rob from stupid retail. Over 70% of retail lose their money in the market and that’s why the CORRUPT SEC allows these mismanaged potentially fraudulent companies to remain listed
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:04 PM
$PPBT LOL $7,000🤣🤣 many of the permabulls have more invested and lost in here 🤣
0 · Reply
StockSmallPenz
StockSmallPenz Oct. 3 at 7:58 PM
$PPBT When RS and dilution? Gil's fingers are itching to do it.
0 · Reply
FBP
FBP Oct. 3 at 7:24 PM
$PPBT this shouldn’t be allowed to stay listed and con more dumb retail but its not illegal to be stupid. The US loves and cherishes a good grift these days
1 · Reply
Latest News on PPBT
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 4 weeks ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 5 weeks ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 2 months ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 3 months ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 4 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 5 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 5 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 7 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 8 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 10 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 10 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 10 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 11 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 11 months ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 1 year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 2 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 2 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 15, 2022, 7:00 AM EST - 3 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 7:53 AM EST - 3 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results

Stocksavior14
Stocksavior14 Oct. 3 at 10:28 PM
$PPBT the permabulls seem to be using alt accounts now but when they are here just to pump. It’s hard for them to change the way they talk to even hide it. Just like the one guy that talks shit to me and calls me cumsavior very similar to the other permabull that would call me cocksavior LOL
1 · Reply
Purplepayday
Purplepayday Oct. 3 at 9:45 PM
$PPBT weird… But, this @Novafudster sound just like Smitty… Any chance that you are related 🤔
1 · Reply
NovaFoster
NovaFoster Oct. 3 at 9:03 PM
$PPBT yes
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:42 PM
$PPBT are you seriously posting explosions and pumping that an institution holds a whopping $7,000 worth of this stock LOL Most permabulls in here have way more than that invested in here at a loss. LOL🤦🏼‍♂️🤦🏼‍♂️🤣🤣
1 · Reply
NovaFoster
NovaFoster Oct. 3 at 8:38 PM
💥 $PPBT 💥 GAMMA Investing just filed a 13F showing 185% increase in their position — now holding 12,654 shares vs 4,430 last quarter. 📊 That’s institutional accumulation, not selling. Float remains tiny, valuation under $10M, and pipeline news could be a game-changer. Funds are quietly loading — the writing is on the wall. 🚀 #PPBT #Biotech
1 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:06 PM
$PPBT we should be getting our non compliance notice soon. Then a 3rd reverse split is on deck LOL
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:06 PM
$PPBT that’s how hedges make money. It’s harder to rob each other since they all have access to more data…. So they have to manipulate and rob from stupid retail. Over 70% of retail lose their money in the market and that’s why the CORRUPT SEC allows these mismanaged potentially fraudulent companies to remain listed
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 8:04 PM
$PPBT LOL $7,000🤣🤣 many of the permabulls have more invested and lost in here 🤣
0 · Reply
StockSmallPenz
StockSmallPenz Oct. 3 at 7:58 PM
$PPBT When RS and dilution? Gil's fingers are itching to do it.
0 · Reply
FBP
FBP Oct. 3 at 7:24 PM
$PPBT this shouldn’t be allowed to stay listed and con more dumb retail but its not illegal to be stupid. The US loves and cherishes a good grift these days
1 · Reply
Purplepayday
Purplepayday Oct. 3 at 6:07 PM
$PPBT it's very very boring to be bullish… But, Smitty was right… Tutes are increasing here 😬
0 · Reply
dogood
dogood Oct. 3 at 4:38 PM
$BINI no one knows why $DFLI running. Wish treatment of run for bulls anytime back to $20 would be nice $ADIL $PPBT
0 · Reply
dogood
dogood Oct. 3 at 4:19 PM
$ADIL shall we have same treatment like $DFLI on both $ADIL and $PPBT
0 · Reply
adamin2
adamin2 Oct. 3 at 1:27 PM
$PPBT Reversing soon .🔜
0 · Reply
Stocksavior14
Stocksavior14 Oct. 3 at 12:16 PM
$ADIL $DFLI $PPBT hey Apple also went up over time and same with Tesla… should we compare PPBT to them also?🤣
1 · Reply
dogood
dogood Oct. 3 at 11:11 AM
$ADIL this $DFLI went from .20 to $1.5 now, shall we get same treatment for $ADIL and $PPBT
0 · Reply
LuckyBoy27
LuckyBoy27 Oct. 3 at 9:47 AM
$PPBT wtf - is Gil deserve to get 350k salary for this worst CEO job. He needs to step aside he is useless. Zero shame as CEO
0 · Reply
JoeBama70
JoeBama70 Oct. 3 at 3:38 AM
$PPBT monthly check in. Yep still a steaming pile ✅
0 · Reply
Stocksavior14
Stocksavior14 Oct. 2 at 9:38 PM
$PPBT love proving how retarded these permabulls are… literally in a previous message from TODAY as well as previous messages, I told this moron that I have a small gamble amount of shares…. And yet these idiots seem to have mental blocks where they can’t understand words because once again, saying I have no shares🤦🏼‍♂️🤦🏼‍♂️🤣🤣 And claiming to know my position while supposedly being new…. And add on that he won’t prove that I bought followers but continues to claim it. Same as when permabulls claimed we needed to give execs bonuses and claimed we were under NDA and claimed we were already bought out.🤣🤣🤣🤣🤣
0 · Reply
Stocksavior14
Stocksavior14 Oct. 2 at 9:35 PM
$PPBT of course I won’t admit to that, because it didn’t happen. You permabulls are just complete retards that can’t get basic common sense through your heads. Go ahead prove that I bought followers, I’d love to see it. You idiots are the same ones that constantly pushed how bullish this shit is and “FABRICATED” insane theories to push which destroyed people
1 · Reply
Limitlesstocks
Limitlesstocks Oct. 2 at 8:25 PM
$PPBT he will never admit to buying followers he’ll always deflect my guy I think his wife pitched in
0 · Reply
Stocksavior14
Stocksavior14 Oct. 2 at 8:06 PM
$PPBT can you remind everyone how much I paid? You must know since you are claiming it…. Can you show the receipt?🤣🤣 Look we get it, you’re an alt account… probably the same person that would always say cocksavior.. That’s why you like to say shit that you have no proof of. Just like you permabulls have done for years
1 · Reply